India’s pharmaceutical industry has emerged as a global powerhouse. It ranks as the third-largest producer of medicines by volume worldwide. The country, dubbed the “pharmacy of the world,” supplies medicines to more than 200 countries and meets about 20% of the world’s generics needs. The Indian pharmaceutical market’s current value was approximately $50-58 billion in 2024. This is a big deal as it means that the market will grow to $130 billion by the end of this decade.
The US-India pharmaceutical relationship tells an equally impressive story. The United States serves as India’s largest healthcare market. Indian pharma exports to the US reached $8.7 billion in FY 2023-24. Indian companies now provide 47% of US generic prescriptions and 15% of biosimilars. These numbers highlight the strong interdependence between these two pharmaceutical giants.
A significant milestone marked this partnership. Indian Prime Minister Narendra Modi and United States President Donald Trump met at the White House on February 13, 2025. They announced the launch of the U.S.-India TRUST (Transforming the Relationship Utilizing Strategic Technology) initiative. This piece explores how this growing partnership reshapes global pharmaceutical supply chains. It enhances quality standards and creates opportunities for state-of-the-art developments in both nations.
1. How India Became a Trusted Pharmaceutical Partner
The United States recognizes India as a trusted pharmaceutical partner due to its regulatory compliance, regional manufacturing excellence, and economic advantages. This partnership is further strengthened by India’s ability to produce high-quality generics at competitive prices, making essential medications more accessible for US patients. Additionally, the collaboration fosters innovation through joint research initiatives, paving the way for breakthroughs in drug development and delivery systems.
a. India’s compliance with US FDA and WHO-GMP standards
The country’s dedication to international quality standards has earned trust in Indian pharmaceuticals. India now houses about 670 US FDA-approved manufacturing facilities, more than any country outside the United States [1]. These facilities make up 25% of all US FDA-approved plants beyond US borders [2]. This robust regulatory network forms the foundation of India’s pharmaceutical credibility.
Quality control remains paramount as the Indian pharmaceutical sector follows World Health Organization Good Manufacturing Practices (WHO-GMP) [3]. While only 19% of India’s 10,500 pharmaceutical manufacturing units hold WHO-GMP certification, the Health Ministry has directed all facilities to meet these standards, showing the country’s steadfast dedication to quality [3].
Encouragingly, the India pharma industry is taking initiative and ongoing training programs and investments in technology are being implemented to enhance compliance and efficiency across the industry. Through these initiatives, the Indian pharma industry is ensuring that even smaller manufacturers can meet global expectations. This commitment to quality not only bolsters India’s reputation but also reassures international partners of the reliability of Indian pharmaceuticals.
b. The role of pharmaceutical industry in Hyderabad, India
Hyderabad shines as India’s pharmaceutical crown jewel. The city has earned recognition as both the “Bulk Drug Capital of India” and “Vaccine Capital of the World” [4]. Local facilities produce more than 40% of India’s bulk drugs [4]. The world’s largest pharmaceutical cluster, “Hyderabad Pharma City,” spans 19,000 acres and employs over 560,000 industry professionals [5].
The city’s success story began in 1961 with Indian Drugs and Pharmaceuticals Ltd. (IDPL). The creation of Jeedimetla industrial estate in 1977 accelerated the region’s pharmaceutical growth [6]. Today, Hyderabad is not only a hub for manufacturing but also a center for research and development, attracting investments from multinational corporations eager to tap into its innovative ecosystem. This vibrant landscape fosters collaboration between academia and industry, further driving advancements in drug discovery and development. As a result, Hyderabad continues to solidify its position as a global leader in the pharmaceutical sector.
c. India’s contribution to US healthcare cost savings
Indian pharmaceutical companies have brought remarkable economic benefits to American healthcare. Their medicines saved $219 billion for the US healthcare system in 2022 [2]. The total savings reached $1.3 trillion between 2013-2022 [2].
Indian manufacturers supply 47% of all generic prescriptions in the US [7] and 15% of biosimilars [8]. Their presence dominates five major therapeutic areas where they provide over half of all prescriptions: hypertension, mental health, lipid regulators, nervous system disorders, and anti-ulcerants [7].
2. Building Trust Through Quality and Compliance
The US-India pharmaceutical relationship runs on quality and compliance that goes beyond economic partnerships. Recent initiatives show how both countries want to deepen their commitment to this vital aspect of working together.
a. Strengthening data integrity and manufacturing practices
Data integrity is the life-blood of pharmaceutical quality assurance. The industry now uses ALCOA+ principles to make sure all records are Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, and Available [9]. These principles are the foundations of patient safety and help meet regulatory requirements through better traceability.
Indian pharmaceutical facilities have moved from paper records to advanced digital systems like laboratory information management systems [10]. Leading manufacturers now use electronic batch records (EBR) that block unauthorized data access through role-based controls and maintain complete audit trails [11].
b. Regulatory reforms and Schedule M updates
The revised Schedule M marks a turning point for Indian pharmaceutical manufacturing. This updated regulation arranges Indian Good Manufacturing Practices (GMP) with WHO standards [12]. It adds mandatory quality risk management frameworks at every manufacturing stage [12].
The path to implementation remains difficult. The government set a compliance deadline of December 31, 2025 [13]. Many smaller manufacturers with annual turnover below Rs. 250 crore struggle with financial and technical barriers [13]. The Health Ministry stands firm that strict enforcement will protect India’s global pharmaceutical reputation [13].
c. Membership in global harmonization bodies like PDG
The Indian Pharmacopeia Commission (IPC) joined the Pharmacopoeial Discussion Group (PDG) in October 2023 [3]. This elite group has pharmacopeias from Europe, Japan, and the United States that work to standardize global pharmaceutical requirements [3].
PDG membership lets India help reduce the load on manufacturers who perform different analytical procedures for different regions [3]. This recognition boosts international acceptance of Indian standards and Indian pharmaceutical products in global markets [3].
d. Transparent supply chains and traceability
We need transparent, traceable pharmaceutical supply chains. Complex global supply networks might lose vital information about origin, production, and integrity [14]. Serialization adds unique serial numbers to pharmaceutical products to spot counterfeits and speed up product recalls [15].
Learn how Biostrategenix can help you build trust with global pharma companies.
WHO estimates that 10.5% of global medicines are substandard or falsified [16]. Track and trace technologies create an unbroken verification chain from manufacturing to dispensing [16]. These systems protect patients and help pharmaceutical companies meet strict regulations worldwide [15].
3. Joint Initiatives Strengthening the Partnership
The strategic importance of US-India pharmaceutical partnerships has grown stronger through collaborative efforts. These initiatives now go beyond traditional trade relationships into substantive institutional frameworks.
a. USP-IPC collaboration and MOU
The United States Pharmacopeia (USP) signed a Memorandum of Understanding with the Indian Pharmacopeia Commission (IPC) to boost pharmaceutical quality standards [17]. This partnership wants to increase awareness about medicine safety and effectiveness while protecting global supply chain integrity [4]. The collaboration gained strength after IPC joined the Pharmacopoeial Discussion Group (PDG) in October 2023. IPC became part of an exclusive international body that focuses on harmonizing global pharmaceutical standards [5].
b. Track 1.5 dialogs and Global Technology Summits
Prime Minister Modi and President Trump laid the groundwork for deeper pharmaceutical cooperation by launching the US-India TRUST (Transforming the Relationship Utilizing Strategic Technology) initiative in February 2025 [6]. Carnegie India hosted several Track 1.5 dialogs during its Global Technology Summit throughout 2025. These dialogs brought together government officials, industry leaders, and policy experts to learn about supply chain resilience strategies [6]. The forums created lasting cooperation habits between industry, academia, and government agencies on both sides [18].
c. Joint R&D and technology transfer programs
Joint innovation efforts depend on funding collaborations as their life-blood. Both governments pledged approximately $90 million over five years for the US-India Global Challenges Institute that supports high-impact R&D partnerships [19]. The National Science Foundation and India’s Department of Science and Technology announced $5 million in grants for joint research projects in telecommunications, autonomous vehicles, and machine learning [19].
d. Advanced market commitments and offtake agreements
Both countries are learning about advanced market commitments where governments guarantee purchases of pharmaceutical products to reduce manufacturer investment risks [6]. Offtake agreements between US firms and Indian manufacturers provide assured markets. These agreements essentially create the pharmaceutical equivalent of the US-India Security of Supply Arrangement [6].
4. Future Opportunities for Deeper Collaboration
The US-India pharmaceutical collaboration moves faster toward state-of-the-art partnerships that span multiple domains.
a. Expanding into biologics and innovative therapies
Indian pharmaceutical companies now lead high-value products like biosimilars and innovative therapies, moving beyond volume-based exports [2]. The Indian biosimilars exports market will grow from its current USD 0.80 billion to USD 4.20 billion by 2030 [2]. Syngene International bought its first biologics manufacturing facility in the United States for USD 36.50 million [7] and expanded its bioreactor capacity to 50,000 liters [7]. Zydus Lifesciences stepped into the global biologics CDMO business by acquiring manufacturing facilities from US-based Agenus Inc. [20].
b. Developing vaccine manufacturing for global markets
India leads global vaccine manufacturing and supplies about 60% of global vaccines [21]. The country demonstrated this leadership during COVID-19 by providing 242 million vaccines to 101 countries [21]. The US, Japan, and Australia now support India’s vaccine manufacturing expansion to ensure fair access in the Indo-Pacific region [21]. CEPI promotes new technologies to create vaccines more efficiently through their “100-day mission” [21].
c. Leveraging digital health and AI in pharma R&D
Artificial intelligence transforms pharmaceutical research in both countries significantly. The global AI in drug discovery market will grow from USD 1.8 billion in 2024 to USD 14 billion by 2033 [22]. Half of Indian pharmaceutical companies now test GenAI initiatives, while a quarter use AI solutions in production [22]. These technologies speed up molecule screening, predict toxicity, and automate literature reviews [23]. India’s digital health sector will surge from USD 2.70 billion in 2022 to USD 37 billion by 2030 [8].
d. Creating resilient supply chains beyond APIs
Both countries aim to reduce their reliance on single-source suppliers, particularly China. India’s Production Linked Incentive (PLI) scheme helps broaden pharma supply chains [24]. The focus remains on building upon India’s GMP- and FDA-compliant facilities rather than duplicating manufacturing infrastructure [6]. Future plans include integrated industrial clusters with complete infrastructure—from raw material sourcing to logistics—and advanced technologies like point-of-care manufacturing and AI-enhanced processes [25].
5. Conclusion
The pharmaceutical partnership between the US and India shows how two global powers can grow together. Indian manufacturers have become trusted suppliers for nearly half of all US generic prescriptions by meeting FDA standards and WHO-GMP certification requirements. American patients saved $219 billion in healthcare costs during 2022 because of this relationship.
Quality initiatives like ALCOA+ data integrity standards and Schedule M updates show both countries’ dedication to excellence. The Indian Pharmacopeia Commission’s membership in the prestigious PDG marks a key milestone that helps create unified standards benefiting manufacturers and patients.
The TRUST initiative launched by Prime Minister Modi and President Trump this year shows a deeper commitment to pharmaceutical cooperation. This framework combines with joint R&D funding and technology transfer programs to create opportunities for state-of-the-art developments in both pharmaceutical ecosystems.
Future collaboration goes beyond traditional generics. Both countries are expanding into biologics, vaccine manufacturing, and AI-driven research. This relationship now focuses on innovation rather than just volume. These advanced partnerships will make supply chains stronger and help solve global healthcare challenges.
Decades of cooperation have built more than just an economic alliance. This partnership has become the life-blood of global healthcare security. Patients worldwide will benefit from continued innovation, affordability, and access as we move through 2025 and beyond.
Key Takeaways
The US-India pharmaceutical partnership has evolved into a strategic alliance that’s reshaping global healthcare through trust, innovation, and substantial economic benefits for both nations.
• India supplies 47% of US generic prescriptions and has delivered $1.3 trillion in healthcare savings between 2013-2022, making it America’s most valuable pharmaceutical partner.
• Trust is built through 670 USFDA-approved facilities in India and compliance with WHO-GMP standards, establishing the foundation for reliable global supply chains.
• The 2025 TRUST initiative and joint R&D funding of $90 million over five years signal a shift from volume-based trade to innovation-driven collaboration in biologics and AI.
• Future opportunities focus on vaccine manufacturing, digital health technologies, and creating resilient supply chains beyond traditional APIs to reduce global dependencies.
• Quality initiatives like ALCOA+ data integrity standards and India’s PDG membership demonstrate both countries’ commitment to harmonized pharmaceutical excellence worldwide.
This partnership represents more than economic cooperation—it’s become a cornerstone of global healthcare security that promises continued innovation, affordability, and improved patient access as the relationship deepens through 2025 and beyond.
References
[1] – https://en.wikipedia.org/wiki/Pharmaceutical_industry_in_India
[2] – https://www.bain.com/insights/healing-the-world-a-roadmap-for-making-india-a-global-pharma-exports-hub/
[3] – https://www.pib.gov.in/PressReleaseIframePage.aspx?PRID=1966349
[4] – https://www.usp.org/usp-india/collaborate
[5] – https://www.pharmabiz.com/NewsDetails.aspx?aid=167010&sid=1
[6] – https://carnegieendowment.org/posts/2025/04/india-us-trust-initiative-a-resilient-pharma-supply-chain?lang=en
[7] – https://www.reuters.com/business/healthcare-pharmaceuticals/indias-syngene-international-acquires-first-us-biologics-facility-50-mln-2025-03-10/
[8] – https://holonlaw.com/business-law/strategies-for-cos-navigating-us-indian-pharma-partnerships/
[9] – https://www.qualityexecutivepartners.com/thought-leadership/the-crucial-nexus-data-integrity-in-pharmaceutical-manufacturing
[10] – https://www.news-medical.net/whitepaper/20241113/The-critical-role-of-data-integrity-in-ensuring-pharmaceutical-quality.aspx
[11] – https://www.vimachem.com/resources/articles/how-to-ensure-data-integrity-in-pharmaceutical-manufacturing/
[12] – https://www.insightsonindia.com/2025/10/06/schedule-m-norms/
[13] – https://www.pharmabiz.com/NewsDetails.aspx?aid=181070&sid=1
[14] – https://www.usp.org/sites/default/files/usp/document/about/public-policy/supply-chain-transparency.pdf
[15] – https://www.supplychainbrain.com/blogs/1-think-tank/post/36976-technology-and-transparency-how-the-pharma-supply-chain-must-adapt
[16] – https://medpak.com/track-and-trace-in-the-pharma-industry/
[17] – https://www.usp.org/news/usp-signs-mou-with-indian-government
[18] – https://www.csis.org/analysis/sustaining-momentum-us-india-technology-ties
[19] – https://in.usembassy.gov/joint-fact-sheet-the-united-states-and-india-continue-to-expand-comprehensive-and-global-strategic-partnership/
[20] – https://www.orfonline.org/expert-speak/tariffs-and-health-security-the-future-of-us-india-pharma-trade
[21] – https://www.investindia.gov.in/team-india-blogs/indias-vaccine-manufacturing-prowess
[22] – https://www.digitalhealthnews.com/from-generics-to-genius-how-ai-is-transforming-indian-pharma
[23] – https://www.sify.com/ai-analytics/from-generics-to-genius-the-ai-revolution-reshaping-indian-pharma/
[24] – https://www.ipa-india.org/article/indo-us-pharma-alliance-time-step
[25] – https://www.contractpharma.com/mitigating-disruptions-in-api-supply-building-resilient-and-redundant-sourcing-strategies/
Leave a Reply